David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$1.2B |
| 2 |
Boston Scientific
BSX
|
+$1.05B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$934M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$924M |
| 5 |
JPMorgan Chase
JPM
|
+$922M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.2B |
| 2 |
NVIDIA
NVDA
|
+$1.58B |
| 3 |
Palantir
PLTR
|
+$901M |
| 4 |
Netflix
NFLX
|
+$883M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$805M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.55% |
| 2 | Consumer Discretionary | 8.97% |
| 3 | Financials | 8.5% |
| 4 | Healthcare | 8.44% |
| 5 | Industrials | 7.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4126
Resources Connection
RGP
$147M
| $179K | ﹤0.01% |
48,034
-162,910
| -77% | -$667K |
|
4127
Lexeo Therapeutics
LXEO
$404M
| $175K | ﹤0.01% |
30,477
-449,728
| -94% | -$3.19M |
|
4128
PUT
Alight
ALIT
$397M
| $175K | ﹤0.01% |
15,000
+10,000
| +200% | +$238K |
|
|
TTAM
4129
Titan America SA
TTAM
$2.78B
| $174K | ﹤0.01% |
+11,584
| New | +$198K |
|
|
BRT
4130
BRT Apartments
BRT
$279M
| $172K | ﹤0.01% |
+12,864
| New | +$187K |
|
|
KC
4131
Kingsoft Cloud Holdings
KC
$3.12B
| $171K | ﹤0.01% |
12,828
-348,772
| -96% | -$4.56M |
|
4132
Ironwood Pharmaceuticals
IRWD
$682M
| $168K | ﹤0.01% |
47,938
-69,508
| -59% | -$285K |
|
4133
Ginkgo Bioworks
DNA
$457M
| $167K | ﹤0.01% |
27,169
-6,603
| -20% | -$54.9K |
|
4134
PUT
AGNC Investment
AGNC
$13B
| $166K | ﹤0.01% |
+16,600
| New | +$184K |
|
|
AGMB
4135
AgomAb Therapeutics NV
AGMB
$631M
| $161K | ﹤0.01% |
+15,326
| New | +$217K |
|
4136
Clover Health Investments
CLOV
$2.18B
| $160K | ﹤0.01% |
91,011
-191,679
| -68% | -$416K |
|
4137
Schrodinger
SDGR
$1.4B
| $160K | ﹤0.01% |
+14,041
| New | +$194K |
|
4138
Independence Realty Trust
IRT
$3.98B
| $159K | ﹤0.01% |
+10,645
| New | +$175K |
|
|
BPAC
4139
Blueport Acquisition Ltd
BPAC
$75.3M
| $156K | ﹤0.01% |
+15,610
| New | +$156K |
|
4140
BCB Bancorp
BCBP
$157M
| $154K | ﹤0.01% |
17,174
-18,421
| -52% | -$151K |
|
4141
Similarweb
SMWB
$793M
| $153K | ﹤0.01% |
58,552
+30,176
| +106% | +$126K |
|
|
FSP
4142
Franklin Street Properties
FSP
$48.2M
| $151K | ﹤0.01% |
227,035
-584,654
| -72% | -$452K |
|
|
PMTRW
4143
Perimeter Acquisition Corp I Warrant
PMTRW
$8.81M
| $150K | ﹤0.01% |
250,000
| – | – |
|
|
ATIIW
4144
Archimedes Tech SPAC Partners II Co Warrant
ATIIW
$17.5M
| $147K | ﹤0.01% |
287,500
| – | – |
|
4145
Forrester Research
FORR
$228M
| $146K | ﹤0.01% |
25,811
-96,513
| -79% | -$660K |
|
|
ADAM
4146
Adamas Trust
ADAM
$886M
| $145K | ﹤0.01% |
+19,732
| New | +$157K |
|
4147
Verastem
VSTM
$621M
| $141K | ﹤0.01% |
26,659
-312,194
| -92% | -$1.93M |
|
4148
Recursion Pharmaceuticals
RXRX
$1.74B
| $141K | ﹤0.01% |
46,008
-43,536
| -49% | -$168K |
|
|
LMRI
4149
Lumexa Imaging Holdings
LMRI
$1.14B
| $141K | ﹤0.01% |
16,418
-183,582
| -92% | -$2.52M |
|
4150
MaxCyte
MXCT
$143M
| $141K | ﹤0.01% |
200,505
-463,451
| -70% | -$433K |
|
Similar funds
David Shaw's Q1 2026 Portfolio in Review
As of Q1 2026, David Shaw held 5,226 positions worth $166B, down 8.8% from $182B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
David Shaw withdrew a net $15.1B in Q1 2026, closing 756 positions and reducing 1,922 holdings. Its most notable exit was iShares Core S&P 500 ETF, an estimated $805M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 19% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, David Shaw opened a new position in Venture Global Inc worth $211M.
- David Shaw's largest Q1 2026 buy was Venture Global Inc: 13,410,074 shares worth $211M.
- David Shaw added most to Broadcom in Q1 2026, an estimated $1.2B increase.
- David Shaw's biggest Q1 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $3.2B.
- David Shaw fully exited iShares Core S&P 500 ETF in Q1 2026, selling an estimated $805M.
- David Shaw's ten largest holdings make up 11% of its $166B portfolio in Q1 2026.
- David Shaw opened 685 new positions and closed 756 in Q1 2026.
- David Shaw's portfolio value fell 8.8% quarter-over-quarter to $166B.
Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.